NRx Pharma shares jump 12% as Zyesami helps prevent cytokine storm in COVID-19
Jul. 19, 2021 7:10 AM ETNRx Pharmaceuticals, Inc. (NRXP)Relief Therapeutics Holding AG (RLFTF)NRx Pharmaceuticals, Inc. (NRXP)By: Mamta Mayani
NRx Pharmaceuticals (NASDAQ:NRXP), up 12% premarket presents evidence that Zyesami (aviptadil) helps prevent "Cytokine Storm" in patients with COVID-19.
In Phase 2b/3 trial, patients treated with placebo experienced a statistically significant elevation in interleukin 6 (IL-6) cytokine levels, whereas those treated with Zyesami had a minimal increase in IL-6.
Change in cytokine level was a prespecified endpoint of the study.
The anti-cytokine effect of Zyesami was additionally associated with a significant decrease in 60-day mortality.
The effect was noted across a diverse set of patients, with different levels of COVID-19 severity and treated in both tertiary care and community hospitals.
NRx has submitted these findings to the FDA as a supplement to its pending application for Emergency Use Authorization, and is submitting a biomarker letter of intent to the FDA as part of its biomarker program.
Zyesami (aviptadil) is being developed in partnership with Relief Therapeutics (OTCQB:RLFTF).